Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2021 Nov-Dec;35(6):3483-3488.
doi: 10.21873/invivo.12649.

Impact of Intraoperative Blood Loss on the Survival of Patients With Stage II/III Colorectal Cancer: A Multicenter Retrospective Study

Hiroshi Tamagawa  1 , Masakatsu Numata  2 , Toru Aoyama  1 , Keisuke Kazama  2 , Yosuke Atsumi  2 , Kenta Iguchi  2 , Sho Sawazaki  3 , Sumito Sato  2 , Kazuki Kano  4 , Takashi Ohshima  4 , Takanobu Yamada  4 , Teni Godai  5 , Akio Higuchi  3 , Hiroyuki Saeki  3 , Norio Yukawa  2 , Yasushi Rino  2
Affiliations
Multicenter Study

Impact of Intraoperative Blood Loss on the Survival of Patients With Stage II/III Colorectal Cancer: A Multicenter Retrospective Study

Hiroshi Tamagawa et al. In Vivo. 2021 Nov-Dec.

Abstract

Background: Resection of the primary lesion with radical lymph node dissection is the most promising treatment avenue for patients with cancer. On the other hand, these procedures often induce excessive intraoperative blood loss (IBL) and require perioperative blood transfusion. The influence of IBL on the long-term postoperative outcomes of patients with digestive cancer is controversial. We investigated the impact of IBL on survival and recurrence after curative surgery in patients with colorectal cancer (CRC) in a single study group.

Patients and methods: In total, 1,597 patients who underwent radical resection for CRC at three group hospitals between 2000 and 2019 were reviewed. Patients were classified into a group with high IBL (≥200 ml) or low IBL (<200 ml). The risk factors for disease-free (DFS) and overall (OS) survival were analyzed.

Results: A total of 489 and 1,108 patients were classified into the high and low IBL groups, respectively. The OS and DFS rates at 5 years after surgery were 89.3% and 63.4%, respectively, for the high IBL group and 96.9% and 77.8% for the low IBL group; these differences were statistically significantly (p<0.001). The multivariate analysis demonstrated that IBL was a significant independent risk factor for OS and DFS.

Conclusion: The amount of IBL was associated with significant differences in the OS and DFS of patients with stage II/III CRC who received curative resection. The surgical procedure, surgical strategy, and perioperative care should be carefully planned to avoid causing IBL.

Keywords: Colorectal cancer; intraoperative blood loss; recurrence; survival.

PubMed Disclaimer

Conflict of interest statement

The Authors declare no conflicts of interest in association with the present study.

Figures

Figure 1
Figure 1. A: Receiver operating characteristic curve analysis to determine the optimal cut-off value of intraoperative blood loss (IBL) in patients who underwent potentially curative surgery for stage II pancreatic cancer. AUC: Area under the curve; CI: confidence interval.
Figure 2
Figure 2. Recurrence-free survival rates in the groups with high (≥200 ml) and low (<200 ml) intraoperative blood loss (IBL). The study population consisted of patients who underwent potentially curative surgery for stage II/III colorectal cancer.
Figure 3
Figure 3. Overall survival rates in the high IBL (≥200 ml) and low IBL (<200 ml) groups. The study population consisted of patients who underwent potentially curative surgery for stage II/III colorectal cancer.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. O’Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004;96(19):1420–1425. doi: 10.1093/jnci/djh275. - DOI - PubMed
    1. Kim MB, Hong TS, Wo JY. Treatment of stage II-III rectal cancer patients. Curr Oncol Rep. 2014;16(1):362. doi: 10.1007/s11912-013-0362-0. - DOI - PubMed
    1. Oki E, Ando K, Kasagi Y, Zaitsu Y, Sugiyama M, Nakashima Y, Sonoda H, Ohgaki K, Saeki H, Maehara Y. Recent advances in multidisciplinary approach for rectal cancer. Int J Clin Oncol. 2015;20(4):641–649. doi: 10.1007/s10147-015-0858-8. - DOI - PubMed
    1. Burrows L, Tartter P. Effect of blood transfusions on colonic malignancy recurrent rate. Lancet. 1982;2(8299):662. doi: 10.1016/s0140-6736(82)92764-7. - DOI - PubMed

Publication types